Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Explore this paper's citation graph
Summary
The combination of pertuzumab plus trastuzumab plus docetaxel, when used as first-line treatment for HER2-positive metastatic breast cancer, significantly prolonged progression-free survival, with no increase in cardiac toxic effects.
- Type
- article
- Published
- 2011-12-07
- Cited by
- 2,428
- References
- 29
- Access
- Open access
- OpenAlex
- https://openalex.org/W2166199281
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:40230894
Keywords
Pertuzumab, Medicine, Trastuzumab, Docetaxel, Metastatic breast cancer
References
- HER2 testing in breast cancer: NCCN Task Force report and recommendations.
- Novel agents and future directions for refractory breast cancer.
- Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
- [New guidelines to evaluate the response to treatment in solid tumors].
- Untangling the ErbB signalling network
- Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.
- Abstract S3-2: Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Antitumor and Safety Analysis of a Randomized Phase II Study ('NeoSphere')
- Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
- Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.
- Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.
- Targeting HER proteins in cancer therapy and the role of the non-target HER3
- Trastuzumab: triumphs and tribulations
- Toxicity and response criteria of the Eastern Cooperative Oncology Group
- Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.
- Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.
- Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.
- ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor
- Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
- Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase
- Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.
Cited by
- Further progress in HER2-directed therapy.
- Toward individualized breast cancer therapy: translating biological concepts to the bedside.
- Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients
- Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function
- Cardiovascular toxicities of biological therapies.
- [Trastuzumab in early breast cancer].
- Optimal targeting of HER2-PI3K signaling in breast cancer: Mechanistic insights and clinical implications
- HER2 therapies and gastric cancer: a step forward.
- What a Tangled Web We Weave: Emerging Resistance Mechanisms to Inhibition of the Phosphoinositide 3-kinase Pathway
- Advances and future directions in the targeting of HER2-positive breast cancer: Implications for the future
- Managing metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer in the older patient.
- The advent of precision therapy in gastrointestinal malignancies: Targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancer
- Outcomes and endpoints in trials of cancer treatment: the past, present, and future.
- Effect of age on drug metabolism in women with breast cancer
- PI3K mutations in breast cancer: prognostic and therapeutic implications
- Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment
- Renal toxicity of anticancer agents targeting HER2 and EGFR
- Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)–Positive Metastatic Breast Cancer: A Randomized Clinical Trial
- Proteolytic single hinge cleavage of pertuzumab impairs its Fc effector function and antitumor activity in vitro and in vivo
- Update Breast Cancer 2018 (Part 4) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer
Related papers
- A new anti-HER2 antibody that enhances the anti-tumor efficacy of trastuzumab and pertuzumab with a distinct mechanism of action.
- Abstract 3477: Pertuzumab in combination with trastuzumab enhanced the anti-tumor activity in HER2-positive human gastric cancers
- Cardiotoxicity after Additional Administration of Pertuzumab following Long-Term Trastuzumab: Report of 2 Cases
- Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
- Adding Pertuzumab to Trastuzumab and Taxanes in HER2 positive breast cancer
- Phase II evaluation of the efficacy and safety of trastuzumab plus pertuzumab therapy in patients with HER2-positive metastatic breast cancer that had progressed during trastuzumab treatment
- Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
- Synergistic antitumor effect of the anti-ErbB2 antibodies trastuzumab and H2-18 on trastuzumab-resistant gastric cancer cells